Envestnet Asset Management Inc. Boosts Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Envestnet Asset Management Inc. lifted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 12.7% in the 2nd quarter, HoldingsChannel reports. The firm owned 48,981 shares of the biotechnology company’s stock after buying an additional 5,531 shares during the quarter. Envestnet Asset Management Inc.’s holdings in United Therapeutics were worth $15,603,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. ClariVest Asset Management LLC lifted its position in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics in the 2nd quarter worth about $30,000. Innealta Capital LLC purchased a new stake in shares of United Therapeutics in the 2nd quarter worth about $33,000. Rise Advisors LLC purchased a new stake in shares of United Therapeutics in the 1st quarter worth about $32,000. Finally, Benjamin F. Edwards & Company Inc. lifted its position in shares of United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 117 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Raymond Dwek sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the transaction, the director now directly owns 1,750 shares of the company’s stock, valued at $569,362.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $45,293.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Raymond Dwek sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the sale, the director now directly owns 1,750 shares of the company’s stock, valued at $569,362.50. The disclosure for this sale can be found here. Insiders sold 114,852 shares of company stock valued at $38,079,259 over the last three months. Insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of a number of recent research reports. LADENBURG THALM/SH SH cut shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. Jefferies Financial Group lifted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday. TD Cowen lifted their price target on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Finally, Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $357.17.

United Therapeutics Stock Up 0.6 %

NASDAQ:UTHR opened at $357.87 on Wednesday. The firm has a 50-day simple moving average of $340.35 and a two-hundred day simple moving average of $293.69. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $366.08. The firm has a market cap of $15.87 billion, a P/E ratio of 16.92, a P/E/G ratio of 1.25 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. During the same period in the previous year, the firm earned $5.24 earnings per share. The firm’s revenue for the quarter was up 19.8% on a year-over-year basis. Analysts predict that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.